METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hormone shots plus vaccine aims to supercharge immune attack on prostate cancer
Disease control Recruiting nowThis phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and resea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New hope for advanced prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New combo aims to stall prostate cancer spread
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug mevrometostat to the standard drug enzalutamide can slow cancer growth better than enzalutamide alone. It involves 900 men with metastatic castration-resistant prostate cancer who have not yet tried certain hormone the…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New radioactive drug aims to slow advanced prostate cancer in major trial
Disease control Recruiting nowThis study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
Experimental CAR t therapy takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New hope for advanced prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding darolutamide to standard treatments can help men with a certain type of advanced prostate cancer (mCRPC) live longer without their cancer getting worse. About 162 participants will receive either standard care alone or standard care plus darolutami…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New pill hopes to stall prostate cancer when other treatments stop working
Disease control Recruiting nowThis phase 2 study tests an oral drug called XL092 (Zanzalintinib) in 32 men with metastatic castration-resistant prostate cancer that has worsened after treatment with Lu-PSMA-617. Participants take one tablet daily at home. The main goal is to see how many men have their cancer…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for tough prostate cancer: targeted drug vs chemo in major trial
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for men with Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for tough prostate cancer: BNT324 takes on chemo
Disease control Recruiting nowThis study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New immunotherapy trial targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new treatment called SYNC-T therapy (SV-102) for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 91 me…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to fight resistant prostate cancer
Disease control Recruiting nowThis study tests a new drug called tinengotinib combined with standard hormone therapies (abiraterone or enzalutamide) in 50 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to usual treatment. The goal is to see if the combination i…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for men with Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Triple threat: new combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to sh…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: VitsGen Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis phase 2 trial tests a two-step treatment for men with metastatic prostate cancer that no longer responds to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-369…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding a targeted radiation drug (lutetium-177 rosopatamab) to standard care can help men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 520 men across multiple countries. Par…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AO-252 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: A2A Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough prostate cancer: Immune-Engaging drug enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to slow prostate cancer spread
Disease control Recruiting nowThis study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough prostate cancer: drug combo aims to delay progression
Disease control Recruiting nowThis study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PARP1 inhibitor IMP1734 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Double radiation attack on resistant prostate cancer enters human testing
Disease control Recruiting nowThis early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose that can be given together. About 42 men with advanced prostate cancer that has stopped responding to hormone therapy will tak…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New radioactive cocktail aims to shrink tough prostate tumors
Disease control Recruiting nowThis Phase 3 trial tests whether adding a radioactive drug called AAA817 to standard hormone therapy can slow cancer growth better than current treatments alone. About 940 men with PSMA-positive metastatic castration resistant prostate cancer will be randomly assigned to receive …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for tough prostate cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough prostate cancer: first human trial of VIR-5500 begins
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Double-Drug attack on Hard-to-Treat prostate cancer begins human testing
Disease control Recruiting nowThis early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combin…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis study tests a new drug called INV-9956 in 84 men with advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants take INV-9956 al…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy targets tough prostate cancer
Disease control Recruiting nowThis early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work bet…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for advanced prostate cancer? early trial tests targeted combo therapy
Disease control Recruiting nowThis early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New T-Cell therapy aims to fight Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase 3 study tests a drug called pasritamig, which helps the body's immune T-cells attack prostate cancer cells. The trial includes 663 men with metastatic castration-resistant prostate cancer, a stage where standard hormone therapy no longer works. Participants receive eit…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new radioactive drug (161Tb-PSMA-I&T) in 12 Taiwanese men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The drug seeks out prostate cancer cells and delivers targeted radiation. The main goal is…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental CAR T-Cell therapy takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called A-CAR032 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo attack on prostate cancer liver spread begins safety trial
Disease control Recruiting nowThis early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have alrea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to fight hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has worsened despite prior treatments. The goal is to see if the combination can shrink tumors, lower PSA levels, or keep the cancer stable for a…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat prostate cancer: early trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: C Ray Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: T.O.A.D. Oncology SA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New prostate cancer drug enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiati…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Full-Life Technologies UK Limited • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat prostate cancer: experimental drug AAA817 faces off against standard care
Disease control Recruiting nowThis study tests an experimental drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has worsened after prior treatments, including a targeted therapy. About 443 participants will be randomly assigned to receive either AAA817 or the …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill takes on tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests an oral drug called DS9051b in 40 people with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for any signs that the drug might shrink t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests a new radioactive drug (lutetium rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or lower PSA levels. About 82 …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Hormone boost then radiation: new hope for tough prostate cancer?
Disease control Recruiting nowThis study tests a new two-step approach for men with advanced prostate cancer that has stopped responding to standard hormone therapy. First, patients receive a high dose of testosterone, followed by a targeted radioactive drug. The goal is to see if this combination is safe and…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo drug trial aims to control hard-to-treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Promising new radiation therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a new drug (AZD2284) that delivers radiation directly to prostate cancer cells. It is for men whose cancer has spread and no longer responds to hormone therapy. The main goals are to check safety and find the right dose, while also measuring how well …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Targeted radiation drug takes aim at bone metastases in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called SKB107 in people with advanced solid tumors that have spread to the bones. The drug delivers a small amount of radiation directly to bone tumors. The study will enroll about 90 adults to check if the drug is safe, how it moves t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis phase 2b trial tests whether adding an experimental drug called ZEN003694 to the standard drug enzalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to abiraterone. About 200 men will be randomly assigned to receive either…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aim…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new two-drug combination for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The drugs are REGN5678, which helps immune cells target cancer cells, and cemiplimab, which removes the br…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New antibody combo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests two experimental drugs, REGN4336 and REGN5678, in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. The first part finds safe doses, and the second part checks how well the combination shrinks tumors. About 228 pa…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough prostate cancer: experimental drug takes on standard treatments
Disease control Recruiting nowThis large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New shot could simplify prostate cancer treatment
Disease control Recruiting nowThis phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a low-dose radioactive drug (177Lu-P17-088) that targets a protein called PSMA on prostate cancer cells. It is for people with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The goal is to see if the treatment can …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple-Drug attack shows promise against tough prostate cancer
Disease control Recruiting nowThis study is for men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. It tests whether adding a targeted radiation drug (225Ac-J591) to immunotherapy (pembrolizumab) and an androgen-receptor inhibitor works better than the im…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New biologic drug JANX014 enters first human trial for tough prostate cancer
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New radioactive drug aims to shrink hard-to-treat prostate cancer
Disease control Recruiting nowThis early study tests a new drug called 3D1015 in men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The main goals are to check safety and find the best dose. About 8 men will take part.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Chunjing Yu • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for hard-to-treat prostate cancer: immunotherapy plus targeted radiation
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a second chemo drug slow prostate cancer growth?
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. The trial compares the usual chemo (docetaxel) alone versus docetaxel plus a platinum chemo drug to see if the combination helps patie…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for advanced cancer: MHB048C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB048C in 200 adults with advanced solid tumors (like prostate cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV, and researchers m…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug SYS6043 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New study tracks Real-World impact of targeted radiation on tough prostate cancers
Disease control Recruiting nowThis study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much their PSA levels drop, how long the cancer stays controlled, and their quality of life during and up to one year after tre…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Supercharged immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new approach for men with metastatic castration-resistant prostate cancer that has spread to the bone and no longer responds to standard treatments. Researchers take a patient's own immune cells (gamma delta T cells), genetically modify them to reco…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Hormone cycling: a new hope for advanced prostate cancer?
Disease control Recruiting nowThis study tests a new way to treat metastatic prostate cancer that has stopped responding to standard hormone therapy. Researchers will give men high doses of testosterone followed by a drug called darolutamide, repeating this cycle to see if it keeps the cancer from growing lon…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR T-Cell therapy takes on metastatic prostate cancer
Disease control Recruiting nowThis study tests a new treatment called AZD0754 for men with metastatic prostate cancer that has spread and is no longer responding to hormone therapy. AZD0754 is a type of immunotherapy where a patient's own immune cells are modified in a lab to better recognize and attack cance…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new treatment called [212Pb]Pb-ADVC001 for men with prostate cancer that has spread to other parts of the body. The treatment delivers a small amount of radiation directly to cancer cells. The study has two parts: first, finding the safest and most effecti…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New prostate cancer drug tested in chinese men – early safety check
Disease control Recruiting nowThis early-phase study tests a new drug called ASP5541 in Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments prednisone and hormone therapy. The main goals are to check the drug's safety and how it is processed by the…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Gut bacteria may hold key to reversing prostate cancer drug resistance
Disease control Recruiting nowThis study tests whether adding dexamethasone or metronidazole to standard therapy can restore sensitivity to abiraterone in men with metastatic prostate cancer that has stopped responding. About 58 men whose cancer progressed on abiraterone will receive either dexamethasone or d…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for tough prostate cancer: HRS-4357 faces off against standard care in major trial
Disease control Recruiting nowThis study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer (PSMA-positive, castration-resistant) that has spread. About 370 men will be randomly assigned to receive either HRS-4357 or a standard therapy. The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for men with Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis early-stage trial is testing a new drug called BMS-986460 in 140 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking fo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New shot every 12 weeks could help men with advanced prostate cancer
Disease control Recruiting nowThis study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, for men with advanced prostate cancer. The drug lowers testosterone, which can help control the cancer. The study aims to find a safe dose and see how well men tolerate it, either…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Targeted radiation zaps Hard-to-Treat prostate cancer in early trial
Disease control Recruiting nowThis study tests a new radioactive drug called 225Ac-LNC1011 in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein (PSMA) on cancer cells to deliver radiation directly. Nine participants w…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new cell therapy called anti-PSMA CAR NK cells in 10 people with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that no longer responds to hormone therapy. The treatment uses immune cells engineered to target a pr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Rana McKay, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for tough prostate cancer? early trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called JANX007 in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 272 men will take part across multiple centers.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new treatment for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment uses specially engineered immune cells (CAR-NK cells) designed to find and attack cancer cells. The main goal is to check if the t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for tough prostate cancer: drug cocktail trial launches
Disease control Recruiting nowThis Phase 2 trial tests a sequence of three drugs—DFMO, high-dose testosterone, and enzalutamide—in 50 men with metastatic castration-resistant prostate cancer that has progressed on standard therapy. The goal is to see if this combination can lower PSA levels and delay cancer g…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill HRS-5041 tested in men with Tough-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called HRS-5041 in 25 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to check the drug's safety and how…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radioactive bullet targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called INR102, which delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will check safety, how the drug moves through…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a second dose of this radioactive drug beat back prostate cancer again?
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. It tests whether giving a second course of a radioactive drug called Lu-PSMA can control the cancer again. Participants will receive the drug every six weeks until their …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug GenSci143 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can control tumor growth. Participants receive the drug by in…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for prostate cancer: extended radioactive therapy shows promise
Disease control Recruiting nowThis early-stage trial is testing a radioactive drug called Lutetium-177 vipivotide tetraxetan in men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets and delivers radiation directly to cancer cells. The study aims …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy aims to control prostate cancer without castration
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of targeted radiation (SBRT) and a radioactive drug called Pluvicto can control metastatic castration-resistant prostate cancer without the need for ongoing hormone therapy. Sixty participants will stop castration and receive th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests an experimental oral drug called HP518 in 84 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then checking how well that dose con…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hinova Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs together in men with advanced prostate cancer that has worsened after standard hormone therapy. HS-20093 is an antibody-drug conjugate that targets a protein on cancer cells, while HRS-5041 is a drug that breaks down androg…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Experimental combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of fasudil hydrochloride and an immunotherapy drug (tirapibep) in 30 men with metastatic castration-resistant prostate cancer that has progressed after standard treatments. Participants receive the drugs alongside standard hormone therapy ov…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: baotai Liang • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a cancer drug shrink tumors in men with a key gene loss?
Disease control Recruiting nowThis phase 2 trial tests the drug bortezomib in 22 men with metastatic castration-resistant prostate cancer that has a specific genetic change (PTEN deletion). The main goal is to see if bortezomib can lower PSA levels by at least 30%. Participants receive bortezomib injections f…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could gut bacteria help fight prostate cancer? new trial tests antibiotic combo
Disease control Recruiting nowThis trial tests whether a short course of four antibiotics can make the standard drug enzalutamide work better in men with metastatic castration-resistant prostate cancer. About 39 men will receive the antibiotics plus enzalutamide to see if the combination is safe and can shrin…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Exercise may fight prostate cancer cells, new study hopes
Disease control Recruiting nowThis study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men who are already on hormone therapy will participate. The goal is to see if exercise can help control the disease, not cure it.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing two new radioactive drugs, 177Lu-P17-087 and 177Lu-P17-088, in 30 people with metastatic castration-resistant prostate cancer that has stopped responding to other treatments. The study first checks how the drug spreads in the body and its safety,…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New imaging agent could reveal which cancers respond to immunotherapy
Diagnosis Recruiting nowThis phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
New PET scan could better spot prostate cancer spread
Diagnosis Recruiting nowThis study tests whether a new type of PET scan (18F-DCFPyL PSMA-PET) can show prostate cancer lesions as well as the standard scan (68Ga-PSMA-11 PET/CT) in 30 men with advanced prostate cancer who are receiving a targeted radiation therapy (177Lu-vipivotide tetraxetan). The goal…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
Can we safely zap more cancer spots? new study pushes radiation limits
Knowledge-focused Recruiting nowThis study is for people with advanced prostate cancer that has spread to bones or lymph nodes and is no longer responding to standard treatments. Researchers want to find the largest total volume of cancer spots that can be safely treated with a precise type of radiation called …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks Olaparib's Real-World impact on prostate cancer
Knowledge-focused Recruiting nowThis study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib in everyday medical practice. Researchers will track how long patients stay on the drug, how well it controls the cancer, and any side effects. The goal is to learn how olapari…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Pluvicto under the microscope: how does it perform in real life?
Knowledge-focused Recruiting nowThis study follows 278 men with advanced prostate cancer who are already receiving Pluvicto as part of their routine care in South Korea. Researchers will monitor side effects and how well the drug controls the cancer over time. No new treatment is given—this is purely an observa…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Real-World study tracks quality of life in men on prostate cancer drug lutathera
Knowledge-focused Recruiting nowThis study follows 500 men with metastatic castration-resistant prostate cancer who are receiving lutetium-177 vipivotide tetraxetan (a radioactive drug) as part of their routine care. Researchers will measure quality of life, pain, and disease progression over time using patient…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Real-World data sought on new prostate cancer drug
Knowledge-focused Recruiting nowThis study follows 300 men with a type of advanced prostate cancer that no longer responds to hormone therapy. Participants receive a targeted radiation treatment called lutetium-177 vipivotide tetraxetan as part of their normal care. Researchers will track how long the cancer st…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Gut bug may reveal who responds to prostate cancer drug
Knowledge-focused Recruiting nowThis study looks at whether a specific gut bacterium, Akkermansia muciniphila, can predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will collect stool and blood samples from 52 men over three months to track…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
5,000 men with advanced prostate cancer to be tracked in new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow about 5,000 men with prostate cancer that has come back or spread. It aims to record which treatments doctors actually use in routine care and how the disease progresses over time. Participants are grouped by their cancer stage, from PSA …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New imaging study aims to unlock secrets of prostate cancer drug resistance
Knowledge-focused Recruiting nowThis study uses special PET/CT scans to see how advanced prostate cancer becomes resistant to newer hormone therapies like enzalutamide or abiraterone. Researchers will track changes in cancer lesions over time in 25 participants. The goal is to better understand resistance patte…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Scientists Fine-Tune radioactive drug dosing for prostate cancer
Knowledge-focused Recruiting nowThis study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Personalized radiation dosing may improve prostate cancer therapy
Knowledge-focused Recruiting nowThis study looks at whether measuring the exact radiation dose delivered to tumors can predict which patients with advanced prostate cancer will respond to a targeted radioactive therapy called Lu-177 PSMA. Researchers will track 110 men over 12 weeks to see if dose calculations …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New study aims to predict which prostate cancer patients benefit from Lu-PSMA therapy
Knowledge-focused Recruiting nowThis study is looking for genetic clues in tumor tissue that could predict whether Lu-PSMA treatment will be effective for men with advanced, castration-resistant prostate cancer. About 120 men who have already tried other treatments will provide tumor samples for analysis. The g…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Centre Jean Perrin • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Real-World data sought on prostate cancer combo therapy
Knowledge-focused Recruiting nowThis study watches how men with a certain advanced prostate cancer (mCRPC) do when taking the drugs olaparib and abiraterone in everyday medical practice. It will track about 250 patients for up to 2 years to see how long they stay on treatment and what happens next. The goal is …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Global study digs into Real-World prostate cancer care
Knowledge-focused Recruiting nowThis study gathers information from medical records of 534 people with metastatic prostate cancer worldwide. It looks at how well different treatments work in everyday practice, including hormone therapy, a radioactive drug called Lutetium-177, and PARP inhibitors. The goal is to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Hospital of Macerata • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can a simple blood test predict prostate cancer return?
Knowledge-focused Recruiting nowThis study is collecting blood samples from 24 men with high-risk localized prostate cancer before they have their prostate removed. Researchers will use a highly sensitive test to look for tiny bits of tumor DNA floating in the blood. The goal is to see if this DNA can help pred…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC